当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

Abstract：

:Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopreventive role. Although curcumin has been shown to inhibit AR expression, its molecular mechanism has not been fully elucidated. In this study, whether curcumin mediates the Wnt/β-catenin signaling pathway with regard to AR/β-catenin interactions was studied. Curcumin was shown to induce significant inhibition of AR expression in a dose-dependent manner. Marked curcumin-induced suppression of β-catenin was shown in the nuclear and cytoplasmic extracts as well as whole cell lysates. Further analysis revealed that phosphorylation of Akt and glycogen synthase kinase-3β were attenuated, but phosphorylated β-catenin was increased after curcumin treatment. Finally, cyclin D1 and c-myc, the target gene of the β-catenin/T-cell factor transcriptional complex, were also decreased. These findings suggest that curcumin modulates the Wnt/β-catenin signaling pathway and might have a significant role in mediating inhibitory effects on LNCaP prostate cancer cells.

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Choi HY,Lim JE,Hong JH

doi

10.1038/pcan.2010.26

subject

Has Abstract

pub_date

2010-12-01 00:00:00

pages

343-9

issue

4

eissn

1365-7852

issn

1476-5608

pii

pcan201026

journal_volume

13

pub_type

杂志文章

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP.

    abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/pcan.2014.13

    authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

    更新日期：2014-09-01 00:00:00

  • The very-high-risk prostate cancer: a contemporary update.

    abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2016.40

    authors： Mano R,Eastham J,Yossepowitch O

    更新日期：2016-12-01 00:00:00

  • Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions.

    abstract：PURPOSES:To address prostate cancer (PCa) detection with respect to the number of biopsy sessions performed, to identify risk factors for detection after a negative biopsy, and to analyze the clinical characteristics of the detected tumors. SCOPE:Only biopsied men (sextant) were included. A total of 1011 biopsy sessio...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500730

    authors： Lujan M,Paez A,Santonja C,Pascual T,Fernandez I,Berenguer A

    更新日期：2004-01-01 00:00:00

  • Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance.

    abstract：BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and c...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-017-0004-y

    authors： Werneburg GT,Kongnyuy M,Halpern DM,Salcedo JM,Kosinski KE,Haas JA,Schiff JT,Corcoran AT,Katz AE

    更新日期：2018-09-01 00:00:00

  • Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.

    abstract：BACKGROUND:The Gleason grading system in prostatectomy specimens following receipt of neoadjuvant therapy has been considered inaccurate. However, with continuing expansion of novel therapeutics, it is important to understand whether the Gleason system can be effectively utilized in this setting. The aim of this study ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2014.30

    authors： Stewart SB,Cheville JC,Sebo TJ,Frank I,Boorjian SA,Thompson RH,Gettman MT,Tollefson MK,Umbriet EC,Psutka SP,Bergstralh EJ,Rangel L,Karnes RJ

    更新日期：2014-12-01 00:00:00

  • Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients.

    abstract：INTRODUCTION:Treatment options for lymph node positive prostate cancer are limited. We retrospectively compared patients who underwent external radiotherapy (ERT) to patients treated by radical prostatectomy (RPX). MATERIALS AND METHODS:A total of 102 lymph node positive patients from the RPX series at Ulm University ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500751

    authors： Kuefer R,Volkmer BG,Loeffler M,Shen RL,Kempf L,Merseburger AS,Gschwend JE,Hautmann RE,Sandler HM,Rubin MA

    更新日期：2004-01-01 00:00:00

  • The microbiome in prostate inflammation and prostate cancer.

    abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0041-1

    authors： Porter CM,Shrestha E,Peiffer LB,Sfanos KS

    更新日期：2018-09-01 00:00:00

  • Adiponectin inhibits oxidative stress in human prostate carcinoma cells.

    abstract：BACKGROUND:Emerging data suggest that obesity increases the risk of aggressive prostate cancer (PC), but the mechanisms underlying this relationship remain to be fully elucidated. Oxidative stress (OS) is a key process in the development and progression of PC. Adiponectin, an adipocyte-specific hormone, circulates at r...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.53

    authors： Lu JP,Hou ZF,Duivenvoorden WC,Whelan K,Honig A,Pinthus JH

    更新日期：2012-03-01 00:00:00

  • Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

    abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.26

    authors： Russo GI,Castelli T,Favilla V,Reale G,Urzì D,Privitera S,Fragalà E,Cimino S,Morgia G

    更新日期：2015-12-01 00:00:00

  • Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

    abstract：BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0060-y

    authors： Miller K,Steger GG,Niepel D,Lüftner D

    更新日期：2018-11-01 00:00:00

  • Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.

    abstract：:To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin ('Zoladex') or two leuprorelin ('Prostap') injections, using 16- or 23-gauge needles, respectively. Median visual analogue...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.pcan.4500778

    authors： Montgomery BS,Borwell JP,Higgins DM

    更新日期：2005-01-01 00:00:00

  • Insulin-like Growth Factor (IGF) Network and Prostate Pathologies.

    abstract：:The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summaris...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500295

    authors： Tatoud R

    更新日期：1999-03-01 00:00:00

  • The role of external radiotherapy in patients treated with permanent prostate brachytherapy.

    abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500552

    authors： Potters L,Fearn P,Kattan M

    更新日期：2002-01-01 00:00:00

  • Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

    abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2015.48

    authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

    更新日期：2016-03-01 00:00:00

  • Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.

    abstract：BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2016.56

    authors： Gökce MI,Sundi D,Schaeffer E,Pettaway C

    更新日期：2017-06-01 00:00:00

  • The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng ml(-1.).

    abstract：BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2014.4

    authors： Nafie S,Mellon JK,Dormer JP,Khan MA

    更新日期：2014-06-01 00:00:00

  • Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.

    abstract：:Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bo...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500846

    authors： Yaturu S,DjeDjos S,Alferos G,Deprisco C

    更新日期：2006-01-01 00:00:00

  • Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer.

    abstract：:Epidemiological studies have suggested an association between low selenium levels and the development of prostate cancer. Human cellular glutathione peroxidase I (hGPX1) is a selenium-dependent enzyme that protects against oxidative damage and its peroxidase activity is a plausible mechanism for cancer prevention by s...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500569

    authors： Kote-Jarai Z,Durocher F,Edwards SM,Hamoudi R,Jackson RA,Ardern-Jones A,Murkin A,Dearnaley DP,Kirby R,Houlston R,Easton DF,Eeles R,CRC\/BPG UK Familial Prostrate Cancer Collaborators.

    更新日期：2002-01-01 00:00:00

  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

    abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0197-3

    authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

    更新日期：2020-09-01 00:00:00

  • Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

    abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500839

    authors： Gould DC,Kirby RS

    更新日期：2006-01-01 00:00:00

  • Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.

    abstract：:A series of 212 prostate specimens of men dead between August 2002-August 2004, have been sectioned in consecutive autopsies and subjected to whole mount analysis in purpose to determine the epidemiology of impalpable prostate cancer in Greece. Impalpable prostate carcinomas were found in 40 cases (18.8%) most in the ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500847

    authors： Stamatiou K,Alevizos A,Perimeni D,Sofras F,Agapitos E

    更新日期：2006-01-01 00:00:00

  • Magnetic resonance imaging in prostate cancer.

    abstract：:With the recently published National Institute of Clinical Excellence guidelines, it is now generally accepted that magnetic resonance imaging (MRI) is the imaging method of choice for staging prostate cancer in patients for whom radical treatment is being considered. MRI offers the single most accurate assessment of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500767

    authors： Heenan SD

    更新日期：2004-01-01 00:00:00

  • Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer.

    abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0234-2

    authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

    更新日期：2020-12-01 00:00:00

  • Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

    abstract：BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.3

    authors： Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

    更新日期：2015-06-01 00:00:00

  • A review of pomegranate in prostate cancer.

    abstract：BACKGROUND:Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METH...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2017.19

    authors： Paller CJ,Pantuck A,Carducci MA

    更新日期：2017-09-01 00:00:00

  • Association between metabolic syndrome, diabetes mellitus and prostate cancer risk.

    abstract：BACKGROUND:The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS:This study consisted of 11 541 men with co...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2012.54

    authors： Lawrence YR,Morag O,Benderly M,Boyko V,Novikov I,Dicker AP,Goldbourt U,Behar S,Barchana M,Wolf I

    更新日期：2013-06-01 00:00:00

  • High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.

    abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.pcan.4500882

    authors： Vargas C,Martínez A,Galalae R,Demanes J,Harsolia A,Schour L,Nuernberg N,Gonzalez J

    更新日期：2006-01-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.61

    authors： Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期：2010-06-01 00:00:00

  • The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.

    abstract：OBJECTIVE:To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor. METHODS:This is a companion study to a prospective randomized trial, N...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.pcan.4500792

    authors： Klotz L,Correia A,Zhang W

    更新日期：2005-01-01 00:00:00

  • ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

    abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.67

    authors： Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

    更新日期：2012-06-01 00:00:00